Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Synonyms
Lévétiracetam
Levetiracetamum
Levetiracetame
Levetiracetam
Brand Names
Levetiracetam Accord
Pharma-levetiracetam
PMS-levetiracetam
Levetiracetam Levetiracetam
Jamp-levetiracetam
Levetiracetam Actavis
Elepsia XR 1500 mg
Levetiracetam Hospira
Levetiracetam Teva
Matever
PHL-levetiracetam
Teva-levetiracetam
Riva-levetiracetam
LEVETIRACETAM Extended-release
Levetiractam
Levetiracetam ER
Levetiracetam 750 mg
Keppra
Pro-levetiracetam - 750
Novo-levetiracetam
Apo-levetiracetam
Levetiracetam Extended-Release
Priva-levetiracetam
Ran-levetiracetam
Auro-levetiracetam
Ava-levetiracetam
Levetiracetam
Van-levetiracetam
Nu-levetiracetam
Levetiracetam 1000 mg
Elepsia XR 1000 mg
Roweepra
Dom-levetiracetam
Levetiracetam in Sodium Chloride
Levetiracetam Sun
LEVETIRACETAM solution
Levetiracetam 250 mg
Levertiracetam
Ag-levetiracetam
Levetiracetam Injection USP
Roweepra XR
Tva-levetiracetam
M-levetiracetam
Pdp-levetiracetam
Levetiracetam Extended Release
Torrent-levetiracetam
Mint-levetiracetam
Pro-levetiracetam - 500
Keppra XR
Bio-levetiracetam
Elepsia XR
Mint-levetiracetam Solution
Nat-levetiracetam
Pro-levetiracetam - 250
Levetiracetam Ratiopharm
Levetiracetam Micro
Sandoz Levetiracetam
Levetiracetam Extended-release
Abbott-levetiracetam
Spritam
Ach-levetiracetam
Nra-levetiracetam
Jamp Levetiracetam Tablets
Levetiracetam Actavis Group
Levetiracetam extended-release
Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Categories
Acetamides
Amides
Anticonvulsants
Central Nervous System Agents
Central Nervous System Depressants
Decreased Central Nervous System Disorganized Electrical Activity
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682